Epistem provides a comprehensive range of established subcutaneous xenograft models, with a focus on epithelial tumour cell lines. Tumour growth and take rates have been established and are routinely used in studies for our oncology clients, either as single agents or in combination with traditional chemotherapies or radiation.

Experienced in a variety of administration routes and schedules, Epistem tailors each assay to the specific requirements of the client and can provide extensive tumour analysis. We also apply our expertise to novel xenograft model development, using either proprietary client, or commercially available, tumour cell lines.

Epithelial tumour cell lines available for xenografting:

• Colon Cancer
  HCT 8, HCT 15, HCT 116, HT29, DLD, LS147T, Colo 205, LoVo, SW620, WiDR
  
• Pancreatic Cancer
  BxPC-3, MiaPaca-2, Panc-1
  
• Head and Neck Squamous Cell Carcinoma
  FaDu, HN5
  
• Prostate Cancer
  PC3, LNCap, CWR22
  
• Lung Cancer
  Calu-6, A549
  
• Breast Cancer
  MCF 7, MD-MB-231, MX-1
  
• Ovarian Cancer
  Skov 3, A2780, Ovcar 3
  
• Melanoma Cancer
  A375, Sk-Mel 37 (subject to licensing)
  
• Other Cancer
  A431 (vulva)

Readouts

• Tumour volume
• Tumour histology
• Immunohistochemical analysis
  - Cell proliferation & apoptosis
  - Angiogenesis
  - Target protein expression
• Gene expression profiling
  - Target gene expression (qRT-PCR)
  - Pathway analysis (Gene Chip)
• Biomarker identification and validation
• FACS analysis